- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:pathogenesis:th1spectrum [02.09.2019] – [A single diagnosis for chronic inflammatory disease] sallieq | home:pathogenesis:th1spectrum [02.10.2019] – [Notes and comments] sallieq | ||
|---|---|---|---|
| Line 500: | Line 500: | ||
| Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components | Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components | ||
| - | (({{pubmed> | + | |
| - | + | ||
| - | | + | |
| - | + | ||
| - | | + | |
| Line 524: | Line 520: | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| + | |||
| + | |||
| + | | ||
| --- //Sallie Q 11.28.2016// | --- //Sallie Q 11.28.2016// | ||
home/pathogenesis/th1spectrum.txt · Last modified: 01.13.2024 by ron
© 2015, Autoimmunity Research Foundation. All Rights Reserved.